Norway pharmacy online: Kjøp av viagra uten resept i Norge på nett.
Jeg kan anbefale en god måte for å øke potens - Cialis. Fungerer mye bedre kjøp propecia Alltid interessant, disse pillene og andre ting i Generelle virkelig har helse til å handle.
Microsoft word - top102007handoutpaacep version.doc
The Top 10 Adult Emergency Medicine Articles from 2007
Bruce A. Macleod, MD, FACEP
Michael A. Turturro, MD, FACEP
A Randomized Controlled Trial of Multi-Slice Coronary Computed
Tomography for Evaluation of Acute Chest Pain. Goldstein JA, Gallagher MJ,
O’Neill WW, et al. J Am Coll Cardiol 2007;49:863-871
: This study sought to compare the safety, diagnostic efficacy, and
efficiency of multi-slice computed tomography (MSCT) with standard diagnostic
evaluation of low-risk acute chest pain patients.
: Over 1 million patients have emergency center evaluations for acute
chest pain annually, at an estimated diagnostic cost of over $10 billion. Multi-slice
computed tomography has a high negative predictive value for exclusion of coronary artery stenoses.
: We randomized patients to MSCT (n = 99) versus SOC (n = 98)
protocols. The MSCT patients with minimal disease were discharged; those with stenosis >70% underwent catheterization, whereas cases with intermediate lesions or non-diagnostic scans underwent stress testing. Outcomes included: safety
(freedom from major adverse events over 6 months), diagnostic efficacy (clinically correct and definitive diagnosis), as well as time and cost of care.
: Both approaches were completely (100%) safe. The MSCT alone
immediately excluded or identified coronary disease as the source of chest pain in 75% of patients, including 67 with normal coronary arteries and 8 with severe
disease referred for invasive evaluation. The remaining 25% of patients required stress testing, owing to intermediate severity lesions or non-diagnostic scans. During
the index visit, MSCT evaluation reduced diagnostic time compared with SOC (3.4 h vs. 15.0 h, p < 0.001) and lowered costs ($1,586 vs. $1,872, p < 0.001).
Importantly, MSCT patients required fewer repeat evaluations for recurrent chest pain (MSCT, 2 of 99 (2.0%) patients vs. SOC, 7 of 99 (7%) patients; p = 0.10).
: Multi-slice computed tomographic coronary angiography can
definitively establish or exclude coronary disease as the cause of chest pain. However, inability to determine the physiological significance of intermediate severity coronary lesions and cases with inadequate image quality are present limitations.
A Clinical Decision Rule to Identify Which Chest Pain Patients Can Safely Be
Removed From Cardiac Monitoring in the Emergency Department. Gatien M,
Perry JJ Stiell IG, et al. Ann Emerg Med 2007; 50 136-143
: We determine the rate of serious arrhythmias in a cohort of
monitored emergency department (ED) chest pain patients and derive a clinical
decision rule that can identify which patients can safely be taken off continuous cardiac monitoring at initial physician assessment.
: A secondary analysis of a prospectively collected cohort was completed in
a university-affiliated tertiary care center. Consecutive patients with a primary complaint of chest pain who underwent cardiac monitoring in the ED in January to
April 2000 were included. Serious arrhythmias were defined as those requiring treatment in the ED. Multivariate recursive partitioning analysis was undertaken to derive a decision rule.
Nine hundred ninety-two consecutive chest pain patients were monitored in
the ED during the study period, of whom 14% and 12% had myocardial infarction and unstable angina, respectively. There were 17 patients (1.7%) with serious
arrhythmias detected in the ED. The following decision rule was derived: patients can be removed from cardiac monitoring if they are pain free at the initial physician
assessment and have a normal or nonspecific ECG result. The rule had 100% sensitivity (95% confidence interval 80% to 100%) for serious arrhythmias. Applying this rule would have allowed physicians to immediately remove 29% of patients from
cardiac monitoring. Conclusion:
Serious arrhythmias are uncommon in monitored ED chest pain
patients. A simple clinical decision rule could be used to safely identify low-risk
patients who can be removed from continuous monitoring if its performance is prospectively validated in an independent patient population.
Randomized, Double-Blind, Placebo-Controlled Trial of Cephalexin for
Treatment of Uncomplicated Skin Abscesses in a Population at Risk for
Community-Acquired Methicillin-Resistant Staphylococcus aureus Infection.
Rajendran PM, Young D, Maurer T, et al. Antimicrob Agents Chemother
Empirical use of beta-lactam antibiotics, the preferred agents for treating uncomplicated skin and soft tissue infections, may no longer be appropriate for these
infections because of the increasing prevalence of community strains of methicillin-resistant Staphylococcus aureus
(MRSA). Retrospective studies, however, suggest
that outcomes are good even when beta-lactams are used. We conducted a randomized, double-blind trial of 166 outpatient subjects comparing placebo to
cephalexin at 500 mg orally four times for 7 days after incision and drainage of skin and soft tissue abscesses. The primary outcome was clinical cure or failure 7 days after incision and drainage. S. aureus
was isolated from 70.4% of abscess cultures.
Of the isolates tested 87.8% were MRSA, 93% of which were positive for Panton-Valentine leucocidin genes. Clinical cure rates were 90.5% (95% confidence interval,
0.82 to 0.96) in the 84 placebo recipients and 84.1% (95% confidence interval, 0.74 to 0.91) in the 82 cephalexin recipients (difference in the two proportions, 0.0006;
95% confidence interval, –0.0461 to 0.0472; P
= 0.25). The 90.5% cure rate observed in the placebo arm and 84.1% cure rate observed in the cephalexin arm
provide strong evidence that antibiotics may be unnecessary after surgical drainage of uncomplicated skin and soft tissue abscesses caused by community strains of MRSA.
Misdiagnosis of Community-Acquired Pneumonia and Inappropriate
Administration of Antibiotics: Side effects of the 4-h antibiotic
administration rule. Kanwar M, Brar N, Khatib R, Fakih M. Chest
The 2003 Infectious Diseases Society of America guidelines for
community-acquired pneumonia (CAP) recommend the initiation of antibiotic therapy
within 4 h of hospitalization. This quality indicator has been linked to the incentive
compensation of third-party payers to hospitals. We evaluated the impact of this recommendation on the diagnosis of CAP and the utilization of antibiotics.
All patients with a hospital admission diagnosis of CAP before publication
of the guidelines (January to June 2003) and after publication of the guidelines (January-June 2005) were included. We collected data on clinical signs and
symptoms on presentation, chest radiograph findings, blood cultures prior to therapy with antibiotics, time to antibiotic administration, pneumonia severity index (PSI)
score, confusion, urea, respiratory rate, BP, and age 65 years (CURB-65), and mortality.
A total of 518 patients were included in the study. More patients in 2005
had a hospital admission diagnosis of CAP without radiographic abnormalities compared to 2003 (2005, 91 patients [28.5%]; 2003, 41 patients [20.6%]; p = 0.04), and more patients received antibiotics within 4 h of triage (2005, 210 patients
[65.8%]; 2003, 107 patients [53.8%]; p = 0.007). Blood cultures prior to antibiotic administration increased (2005, 220 patients [69.6%]; 2003, 93 patients [46.7%]; p
< 0.001). However, the final diagnosis of CAP dropped to 58.9% in 2005 from 75.9% in 2003 (p < 0.001). The mean (± SD) antibiotic utilization per patient increased to
1.66 ± 0.54 in 2005 compared to 1.39 ± 0.58 in 2003 (p < 0.001). There were no significant differences in PSI or CURB-65 scores, or mortality.
Linking antibiotic administration within 4 h of hospital admission (as a
quality indicator) to financial compensation may result in an inaccurate diagnosis of CAP, inappropriate utilization of antibiotics, and thus less than optimal care.
Antibiotics and Topical Nasal Steroid for Treatment of Acute Maxillary
Sinusitis Williamson IA, Rumsby K, Benge S, et al. JAMA 2007;298:2487-
Acute sinusitis is a common clinical problem that usually results in a
prescription for antibiotics but the role of antibiotics is debated. Anti-inflammatory
drugs such as topical steroids may be beneficial but are underresearched.
To determine the effectiveness of amoxicillin and topical budesonide in
acute maxillary sinusitis.
Design, Setting, and Patients
A double-blind, randomized, placebo-controlled
factorial trial of 240 adults (aged 16 years) with acute nonrecurrent sinusitis (had
2 diagnostic criteria: purulent rhinorrhea with unilateral predominance, local pain
with unilateral predominance, purulent rhinorrhea bilateral, presence of pus in the nasal cavity) at 58 family practices (74 family physicians) between November 2001
and November 2005. Patients were randomized to 1 of 4 treatment groups: antibiotic and nasal steroid; placebo antibiotic and nasal steroid; antibiotic and placebo nasal
steroid; placebo antibiotic and placebo nasal steroid.
A dose of 500 mg of amoxicillin 3 times per day for 7 days and 200
µg of budesonide in each nostril once per day for 10 days.
Main Outcome Measures
Proportion clinically cured at day 10 using patient
symptom diaries and the duration and severity of symptoms.
The proportions of patients with symptoms lasting 10 or more days were 29
of 100 (29%) for amoxicillin vs 36 of 107 (33.6%) for no amoxicillin (adjusted odds
ratio, 0.99; 95% confidence interval, 0.57-1.73). The proportions of patients with symptoms lasting 10 or more days were 32 of 102 (31.4%) for topical budesonide vs
33 of 105 (31.4%) for no budesonide (adjusted odds ratio, 0.93; 95% confidence interval, 0.54-1.62). Secondary analysis suggested that nasal steroids were
significantly more effective in patients with less severe symptoms at baseline.
Neither an antibiotic nor a topical steroid alone or in combination was
effective as a treatment for acute sinusitis in the primary care setting.
Antibiotic Use for Emergency Department Patients with Upper Respiratory
Tract Infections: Prescribing Practices, Patient Expectations and Patient
Satisfaction. Ong S, Nakase J, Moran G, et al. Ann Emerg Med 2007;50:213-
Physicians often prescribe antibiotics to patients even when there
is no clear indication for their use. Previous studies examining antibiotic use in acute bronchitis and upper respiratory infections have been conducted in primary care
settings. We evaluate the factors that physicians in the emergency department (ED) consider when prescribing antibiotics (eg, patient expectations) and the factors associated with patient satisfaction.
Ten academic EDs enrolled adults and children presenting with symptoms
consistent with upper respiratory infection. Enrolled patients were interviewed before their physician encounter and were reinterviewed before discharge and 2 weeks
later. Physicians were interviewed about factors that influenced their management decisions, including their perceptions of patients’ expectations. Patients with a single
diagnosis of uncomplicated acute bronchitis or upper respiratory infection were
included for analysis. Results
: Of 272 patients enrolled, 68% of bronchitis patients and 9% of upper
respiratory infection patients received antibiotics. Physicians were more likely to
prescribe antibiotics when they believed that patients expected them (odds ratio [OR] 5.3; 95% confidence interval [CI] 2.9 to 9.6), although they were able to
correctly identify only 27% of the patients who expected antibiotics. Satisfaction with the ED visit was reported by 87% of patients who received antibiotics and 89% of
those not receiving antibiotics. Satisfaction with the visit was reported by 92% of patients who believed they had a better understanding of their illness but only by 72% of those who thought they had no better understanding (OR 4.4; 95% CI 2.0 to
: Physicians in our academic EDs prescribed antibiotics to 68% of acute
bronchitis patients and to fewer than 10% of upper respiratory infection patients.
Physicians were more likely to prescribe antibiotics to patients who they believed expected them, although they correctly identified only about 1 in 4 of those patients.
Patient satisfaction was not related to receipt of antibiotics but was related to the belief they had a better understanding of their illness.
Early Treatment with Prednisolone or Acyclovir in Bell's Palsy. Sullivan FM,
Swan IRC, Donnan PT et al. N Engl J Med 2007;357:1598-1607.
Corticosteroids and antiviral agents are widely used to treat the early
stages of idiopathic facial paralysis (i.e., Bell's palsy), but their effectiveness is
We conducted a double-blind, placebo-controlled, randomized, factorial
trial involving patients with Bell's palsy who were recruited within 72 hours after the
onset of symptoms. Patients were randomly assigned to receive 10 days of treatment
with prednisolone, acyclovir, both agents, or placebo. The primary outcome was recovery of facial function, as rated on the House–Brackmann scale. Secondary
outcomes included quality of life, appearance, and pain.
Final outcomes were assessed for 496 of 551 patients who underwent
randomization. At 3 months, the proportions of patients who had recovered facial
function were 83.0% in the prednisolone group as compared with 63.6% among patients who did not receive prednisolone (P<0.001) and 71.2% in the acyclovir
group as compared with 75.7% among patients who did not receive acyclovir (adjusted P=0.50). After 9 months, these proportions were 94.4% for prednisolone
and 81.6% for no prednisolone (P<0.001) and 85.4% for acyclovir and 90.8% for no acyclovir (adjusted P=0.10). For patients treated with both drugs, the proportions were 79.7% at 3 months (P<0.001) and 92.7% at 9 months (P<0.001). There were
no clinically significant differences between the treatment groups in secondary outcomes. There were no serious adverse events in any group.
In patients with Bell's palsy, early treatment with prednisolone
significantly improves the chances of complete recovery at 3 and 9 months. There is no evidence of a benefit of acyclovir given alone or an additional benefit of acyclovir
Comparison of Oral Prednisolone/Paracetamol and Oral
Indomethacin/Paracetamol Combination Therapy in the Treatment of Acute
Goutlike Arthritis: A Double-Blind, Randomized, Controlled Trial. Man CY,
Cheung ITF, Cameron PA, Rainer TH. Ann Emerg Med 2007;49:490:670-677
: We compare the analgesic efficacy and adverse effects of oral
prednisolone/acetaminophen and oral indomethacin/acetaminophen combination therapy in the treatment of acute goutlike arthritis in patients presenting to an
emergency department (ED). Methods
: This is a double-blind, randomized, controlled study in a university
hospital emergency department (ED) in the New Territories of Hong Kong. Patients older than 17 years and presenting between February 1, 2003, and June 30, 2004,
with a clinical diagnosis of goutlike arthritis were randomized to receive either oral prednisolone/acetaminophen or oral indomethacin/acetaminophen combination
therapy. Primary outcome measures were pain scores, time to resolution of symptoms and signs, and adverse effects. Secondary outcome measures were the
need for additional acetaminophen and relapse rate. Results
: There were 90 patients randomized: 46 patients to the indomethacin group
and 44 patients to the prednisolone group. Baseline characteristics, including pain scores, were similar in the 2 groups. Both treatment groups had a similar decrease in
pain score in the ED. The mean rate of decrease in pain score with activity for indomethacin was −1.7±1.6 (SD) mm per day and for prednisolone was −2.9±2.0
(SD) mm per day (mean difference 1.2 mm/day; 95% confidence interval 0.4 to 2.0 mm/day; P
=.0026). Although these differences were statistically significant, at no
time was the difference in mean pain score greater than 13 mm. Therefore, it is unclear whether these differences are clinically significant. The mean total dose of acetaminophen consumed by the prednisolone group was significantly more than in
the indomethacin group (mean 10.3 g, range 1 to 21 g versus mean 6.4 g, range 1 to 21 g). Twenty-nine patients in the indomethacin group and 12 patients in the
prednisolone group experienced adverse effects (P
<.05). The commonest adverse effects in the indomethacin group were nausea, indigestion, epigastric pain,
dizziness, and gastrointestinal bleeding (N=5; 11%). None of the patients in the prednisolone group developed gastrointestinal bleeding. The relapse rate for both
groups was similar. Conclusion
: In the treatment of acute goutlike arthritis, oral
prednisolone/acetaminophen combination is as effective as oral indomethacin/acetaminophen combination in relieving pain but is associated with
Emergency Department Crowding Is Associated With Poor Care for Patients
With Severe Pain. Pines JM, Hollander JH: Ann Emerg Med 2008;51:1-5
: We study the impact of emergency department (ED) crowding on
delays in treatment and nontreatment for patients with severe pain. Methods
: We performed a retrospective cohort study of all patients presenting with
severe pain to an inner-city, teaching ED during 17 months. Poor care was defined
by 3 outcomes: not receiving treatment with pain medication while in the ED, a delay (>1 hour) from triage to first pain medication, and a delay (>1 hour) from room
placement to first pain medication. Three validated crowding measures were assigned to each patient at triage. Logistic regression was used to test the
association between crowding and outcomes. Results:
In 13,758 patients with severe pain, the mean age was 39 years (SD 16
years), 73% were black, and 64% were female patients. Half (49%) of the patients received pain medication. Of those treated, 3,965 (59%) experienced delays in
treatment from triage and 1,319 (20%) experienced delays from time of room placement. After controlling for factors associated with the ED treatment of pain
(race, sex, severity, and older age), nontreatment was independently associated with waiting room number (odds ratio [OR] 1.03 for each additional waiting patient;
95% confidence interval [CI] 1.02 to 1.03) and occupancy rate (OR 1.01 for each 10% increase in occupancy; 95% CI 0.99 to 1.04). Increasing waiting room number and occupancy rate also independently predicted delays in pain medication from
triage (OR 1.05 for each waiting patient, 95% CI 1.04 to 1.06; OR 1.18 for each 10% increase in occupancy; 95% CI 1.15 to 1.21) and delay in pain medication from
room placement (OR 1.02 for each waiting patient, 95% CI 1.01 to 1.03; OR 1.06 for each 10% increase in occupancy, 95% CI 1.04 to 1.08).
ED crowding is associated with poor quality of care in patients with
severe pain, with respect to total lack of treatment and delay until treatment.
Sending Low-Acuity Patients Away From the ED: Closing the Door or
Stemming the Tide? Greene J. Ann Emerg Med 2007;49:317-319
Diverting low-acuity patients from the emergency department (ED) has become a hot-button issue for the American College of Emergency Physicians (ACEP), with some members contending it is an obvious necessity and others opining that it tears
at the fabric of emergency medicine's mission.
Emergency physicians are struggling to maintain an open-door policy in the face of large numbers of patients who use the emergency department for minor ailments
better treated by a primary care doctor. Some hospitals' policies to send those patients elsewhere are raising fears that this selective process will erode the
Principio Attivo Descrizione prodotto generico Note Distribuzione Appropriatezza prescrittiva Terapeutico disponibile A - GASTROINTESTINALI Tutti i PPI sono di uguale efficacia se utilizzati a dosi Come per tutti i farmaci, anche per i PPI ci possono essere variabilità individuali tra i diversi pazienti. I PPI devono essere assunti lontano dai pasti, preferibilmente
Je soussigné Jean-Pierre MATHONNET, Pharmacien Responsable, certifie que le produit suivant a été enregistré à la DGCCRF et que sa composition est conforme au décret européen 2006-352 des compléments alimentaires. Dénomination produit Composition HAPPY.CO Programme CLA ,Thé vert, Guarana, Frêne, Queue de cerises, PACHIRA SLIM Orthosiphon, Café cru, Ananas, Spiruline, Vigne